P C I

In Vivo Tumor Progression Studies: The Relative Strengths of available Imaging Modalities and Reporter Constructs

Preclinical Imaging
Combining preclinical in vivo imaging modalities offers the opportunity to synergize the strengths of each in one experiment. In this webinar, Dr. Kah-Wye Peng, Chief Operating Officer at Imanis Life Sciences, will outline the range of products and reagents offered by the company for use in optical imaging. Co-presenter Dr. Andrew Van Praagh, Field Applications Scientist, from Bruker BioSpin, will demonstrate some specific examples of preclinical research drawing together the technology from both companies, including Bruker’s multimodal Xtreme II imaging system.
This webinar took place on June 08th 2018

Register to download slides & media

Overview

In this webinar, Dr. Kah-Wye Peng, Chief Operating Officer at Imanis Life Sciences, will outline the range of products and genetic reporters systems and reagents offered by the company for use in optical and nuclear imaging. Imanis provide reporter gene cell lines, lentiviruses, oncolytic viruses, antibodies, lentiviral plasmids and custom products to support non-invasive reporter gene imaging and oncolytic virology research.

Dr. Peng will be joined on the webinar by co-presenter Dr. Andrew Van Praagh, Field Applications Scientist, from Bruker BioSpin, who will describe some of the research facilitated by bringing together the products and reagents offered by Imanis with the state-of-the-art multimodal imaging technology delivered by Bruker.

What you will discover

During this webinar, Peng will outline the various products her company have been making available to researchers since founding in 2012. This includes facilitating imaging with fluorescence, bioluminescence and radioisotopes. She will highlight the benefits of multimodal imaging, including early detection, high sensitivity and accelerated drug development. The webinar will also illustrate how the products offered by Imanis Life Sciences perfectly complement Bruker’s technology. 

Dr. Van Praagh will demonstrate some specific examples of preclinical research drawing together the technology from both companies. He will also highlight how the Bruker In Vivo Xtreme II imaging system combines four imaging modalities – luminescence, fluorescence, radioisotope imaging and X-ray – in one to deliver an unparalleled level of sensitivity, speed and versatility in preclinical imaging. Further, the relative strengths for Optical, microCT, and MRI imaging in tumor progression studies will be reviewed.

Key topics

  • Applications of the technology
  • Reporters for multimodal imaging
  • Longitudinal tumor imaging
  • Bruker’s In Vivo Xtreme II Optical/X-ray system

Who should attend

This webinar will interest oncologists and cancer researchers as well as people working in imaging and the virus gene therapy market. It is also highly relevant for people working in drug development, particularly in the areas of oncology and infectious diseases.

Speaker

Dr. Kah-Wye Peng
Chief Operating Officer Imanis Life Sciences
Dr. Kah-Whye Peng was a founding member of Imanis Life Sciences and serves as the Chief Operating Officer and Secretary. She is also a Professor of Oncology at the Mayo Clinic where her lab focus on the development of viral-based novel therapeutics for ovarian cancer and multiple myeloma.
Dr. Andrew Van Praagh
Field Applications Scientist Bruker BioSpin
Dr. Andrew Van Praagh has a PhD from the University of Massachusetts, Amherst and has been working in the field of multimodal optical imaging for over seven years. Since 2014, he has served as Lab Manager for the Preclinical Imaging Lab at Bruker BioSpin.